PEGLOTICASE for treatment of refractory GOUT!!! - USMLE Forums
USMLE Forums Logo
USMLE Forums         Your Reliable USMLE Online Community     Members     Posts
Home
USMLE Articles
USMLE News
USMLE Polls
USMLE Books
USMLE Apps
Go Back   USMLE Forums > USMLE Step 2 CK Forum

USMLE Step 2 CK Forum USMLE Step 2 CK Discussion Forum: Let's talk about anything related to USMLE Step 2 CK exam


Reply
 
Thread Tools Search this Thread Display Modes
  #1  
Old 01-10-2012
dr.digant's Avatar
USMLE Forums Addict
 
Steps History: Step 1 Only
Posts: 127
Threads: 21
Thanked 103 Times in 53 Posts
Reputation: 113
Default PEGLOTICASE for treatment of refractory GOUT!!!

Pegloticase (trade name Krystexxa, formerly Puricase)[1] is a drug for the treatment of severe, treatment-refractory, chronic gout, developed by Savient Pharmaceuticals. In September 2010, the FDA approved pegloticase for marketing in the United States after two clinical trials demonstrated that the drug lowered uric acid levels and reduced deposits of uric acid crystals in joints and soft tissue.

MECHANISM:
Pegloticase is a recombinant porcine-like uricase. Similarly to rasburicase, both enzymes metabolise uric acid to allantoin. This reduces the risk of precipitates, since allantoin is five to ten times more soluble than uric acid.
In contrast to rasburicase, pegloticase is pegylated to increase its elimination half life from about eight hours to ten or twelve days and to decrease the immunogenicity of the foreign uricase protein. This modification allows for an application just once every two to four weeks, making this drug suitable for long-term treatment.
Reply With Quote Quick reply to this message
The above post was thanked by:
dinosaur108 (01-10-2012), nervous system (11-11-2016), samstar (01-11-2012), thensg300 (01-12-2016)



  #2  
Old 01-10-2012
dr.digant's Avatar
USMLE Forums Addict
 
Steps History: Step 1 Only
Posts: 127
Threads: 21
Thanked 103 Times in 53 Posts
Reputation: 113
Default

Guys this post is just for extra information
Reply With Quote Quick reply to this message
The above post was thanked by:
mayursn39 (01-10-2012)



Reply

Quick Reply
Message:
Options

Register Now

In order to be able to post messages on the USMLE Forums forums, you must first register.
Please enter your desired user name, your email address and other required details in the form below.
User Name:
Password
Please enter a password for your user account. Note that passwords are case-sensitive.
Password:
Confirm Password:
Email Address
Please enter a valid email address for yourself.
Email Address:
Medical School
Choose "---" if you don't want to tell. AMG for US & Canadian medical schools. IMG for all other medical schools.
USMLE Steps History
What steps finished! Example: 1+CK+CS+3 = Passed Step 1, Step 2 CK, Step 2 CS, and Step 3.

Choose "---" if you don't want to tell.

Favorite USMLE Books
What USMLE books you really think are useful. Leave blank if you don't want to tell.
Location
Where you live. Leave blank if you don't want to tell.

Log-in

Human Verification

In order to verify that you are a human and not a spam bot, please enter the answer into the following box below based on the instructions contained in the graphic.



Thread Tools Search this Thread
Search this Thread:

Advanced Search
Display Modes


Similar Threads
Thread Thread Starter Forum Replies Last Post
Treatment of HCV Seetal USMLE Step 2 CK Forum 12 10-30-2011 10:20 PM
Absolute Refractory Period versus Effective Refractory Period monsalg2502 USMLE Step 1 Forum 2 07-05-2011 07:04 PM
Which NSAID is contraindicated in Gout mtoi USMLE Step 1 Forum 2 11-21-2010 05:04 PM
Treatment of ITP ?? weta USMLE Step 2 CK Forum 2 08-17-2010 01:02 AM
Hemochromatosis Association with Gout! lynk USMLE Step 1 Forum 2 06-07-2010 02:23 PM

RSS Feed
Find Us on Facebook
vBulletin Security provided by vBSecurity v2.2.2 (Pro) - vBulletin Mods & Addons Copyright © 2017 DragonByte Technologies Ltd.

USMLE® & other trade marks belong to their respective owners, read full disclaimer
USMLE Forums created under Creative Commons 3.0 License. (2009-2014)